BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

950 related articles for article (PubMed ID: 19303137)

  • 1. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
    Dematteo RP; Ballman KV; Antonescu CR; Maki RG; Pisters PW; Demetri GD; Blackstein ME; Blanke CD; von Mehren M; Brennan MF; Patel S; McCarter MD; Polikoff JA; Tan BR; Owzar K;
    Lancet; 2009 Mar; 373(9669):1097-104. PubMed ID: 19303137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
    JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors.
    Cohen MH; Cortazar P; Justice R; Pazdur R
    Oncologist; 2010; 15(3):300-7. PubMed ID: 20200041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.
    Blay JY; Shen L; Kang YK; Rutkowski P; Qin S; Nosov D; Wan D; Trent J; Srimuninnimit V; Pápai Z; Le Cesne A; Novick S; Taningco L; Mo S; Green S; Reichardt P; Demetri GD
    Lancet Oncol; 2015 May; 16(5):550-60. PubMed ID: 25882987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
    Demetri GD; van Oosterom AT; Garrett CR; Blackstein ME; Shah MH; Verweij J; McArthur G; Judson IR; Heinrich MC; Morgan JA; Desai J; Fletcher CD; George S; Bello CL; Huang X; Baum CM; Casali PG
    Lancet; 2006 Oct; 368(9544):1329-38. PubMed ID: 17046465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
    Corless CL; Ballman KV; Antonescu CR; Kolesnikova V; Maki RG; Pisters PW; Blackstein ME; Blanke CD; Demetri GD; Heinrich MC; von Mehren M; Patel S; McCarter MD; Owzar K; DeMatteo RP
    J Clin Oncol; 2014 May; 32(15):1563-70. PubMed ID: 24638003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
    Kang YK; Ryu MH; Yoo C; Ryoo BY; Kim HJ; Lee JJ; Nam BH; Ramaiya N; Jagannathan J; Demetri GD
    Lancet Oncol; 2013 Nov; 14(12):1175-82. PubMed ID: 24140183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
    Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib: as adjuvant therapy for gastrointestinal stromal tumour.
    Sanford M; Scott LJ
    Drugs; 2010 Oct; 70(15):1963-72. PubMed ID: 20883053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients.
    Kanda T; Nishida T; Wada N; Kobayashi O; Yamamoto M; Sawaki A; Boku N; Koseki M; Doi T; Toh Y; Kakeji Y; Sugiyama T; Komatsu Y; Kikuchi S; Ogoshi K; Katai H; Miyachi K; Hirota S; Ohtsu A
    Int J Clin Oncol; 2013 Feb; 18(1):38-45. PubMed ID: 22105894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management.
    Joensuu H
    Drugs; 2012 Oct; 72(15):1953-63. PubMed ID: 22994537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.
    Cohen MH; Johnson JR; Justice R; Pazdur R
    Oncologist; 2012; 17(7):992-7. PubMed ID: 22643537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
    DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
    Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
    Le Cesne A; Ray-Coquard I; Bui BN; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Cioffi A; Emile JF; Chabaud S; Pérol D; Blay JY;
    Lancet Oncol; 2010 Oct; 11(10):942-9. PubMed ID: 20864406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Blay JY; Serrano C; Heinrich MC; Zalcberg J; Bauer S; Gelderblom H; Schöffski P; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Meade J; Shi K; Ruiz-Soto R; George S; von Mehren M
    Lancet Oncol; 2020 Jul; 21(7):923-934. PubMed ID: 32511981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
    Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
    JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
    Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
    J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors].
    Heger U; Weitz J; Lordick F
    Chirurg; 2008 Jul; 79(7):630-7. PubMed ID: 18548219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
    Joensuu H; Eriksson M; Hall KS; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Ballman KV; Leinonen M; DeMatteo RP; Reichardt P
    Cancer; 2014 Aug; 120(15):2325-33. PubMed ID: 24737415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.